Trends & Forecasts

Can making clinical trials more family friendly help increase the number of female participants?

As mental health disorders escalate, pharmaceutical innovators can harness advanced tools to accelerate much-needed treatments.

Our latest news roundup reports on Roche’s US investment, a lawsuit against Vertex Pharmaceuticals, and more.

EMA reflection paper considers elimination of routine comparative efficacy studies for biosimilars.

Trump signs executive order on lowering drug prices and amends Medicare price negotiation for small molecule drugs.

The political situation in the US and its impact on science and medicine is changing rapidly. Here’s a quick look at the latest developments.

We dive into the archive of 2022 for insight and inspiration – this time with Kowid Ho

Looking ahead to the next 5–10 years, what will be the key disruptors and/or what can be improved upon in the pharma industry?

We ask James Chambers from Tufts Medical Center about the challenges faced by biosimilars in the US.

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems; we ask experts about the future of advanced medicine.